NORADRENERGIC MECHANISMS AND THE CARDIOVASCULAR ACTIONS OF NITROGLYCERIN

被引:26
作者
MA, SX
SCHMID, PG
LONG, JP
机构
[1] UNIV IOWA,COLL MED,CTR CARDIOVASC,DEPT PHARMACOL,IOWA CITY,IA 52242
[2] UNIV IOWA,DEPT VET AFFAIRS MED CTR,IOWA CITY,IA 52242
关键词
NITROGLYCERIN; SODIUM NITROPRUSSIDE; NITRIC OXIDE; NORADRENERGIC ACTIVITY; CARDIOVASCULAR ACTION; CNS;
D O I
10.1016/0024-3205(94)00325-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In this article we review noradrenergic activities of nitroglycerin in the central and peripheral nervous systems. Nitroglycerin may cause paradoxical bradycardia and occasional life threatening hypotension in patients. Intracisternal injections and microinjections of nitroglycerin into nucleus tractus solitarii produce hypotension and bradycardia, effects which mimic the baroreflex and may involve central noradrenergic mechanisms. The drug also triggers an alpha(2)-adrenoceptor-mediated sympatho-inhibition reflex through vagal afferents. Nitroglycerin mimics biological responses associated with sympathetic neuronal activity, e.g., increase in outflow of norepinephrine and its metabolites from perfused guinea pig atria, medulla-pons tissue and cerebrospinal fluid. The sympathomimetic effects of nitroglycerin are antagonized by pre-treatment with yohimbine or rauwolscine. Clinical studies and animal experiments show that hemodynamics of nitroglycerin and sodium nitroprusside are different. Nitroglycerin is lipophilic and the compounds readily enters cells to form nitric oxide, but sodium nitroprusside is very hydrophilic and the compound has difficulty crossing membranes. Thus, intravenous nitroglycerin-induced increases in central noradrenergic activation and inhibitory reflexes may account for at least some of the therapeutic actions and side effects of the drug. In contrast, minimal central responses are produced by intravenous administration of sodium nitroprusside.
引用
收藏
页码:1595 / 1603
页数:9
相关论文
共 28 条
[1]  
ANTONACCIO MJ, 1984, CARDIOVASCULAR PHARM, P155
[2]  
AXELSSON KL, 1986, ACTA PHARMACOL TOX, V59, P121
[3]   CONTROL OF CARDIAC-MUSCLE CELL-FUNCTION BY AN ENDOGENOUS NITRIC-OXIDE SIGNALING SYSTEM [J].
BALLIGAND, JL ;
KELLY, RA ;
MARSDEN, PA ;
SMITH, TW ;
MICHEL, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (01) :347-351
[4]   ALPHA-ADRENERGIC DRUGS - PHARMACOLOGICAL TOOLS FOR THE STUDY OF THE CENTRAL VASOMOTOR CONTROL [J].
BOUSQUET, P ;
SCHWARTZ, J .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (09) :1459-1465
[5]   NITRIC-OXIDE ATTENUATES CARDIAC MYOCYTE CONTRACTION [J].
BRADY, AJB ;
WARREN, JB ;
POOLEWILSON, PA ;
WILLIAMS, TJ ;
HARDING, SE .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (01) :H176-H182
[6]   NITROGLYCERIN-INDUCED HYPOTENSION, BRADYCARDIA, AND ASYSTOLE - REPORT OF A CASE AND REVIEW OF THE LITERATURE [J].
BRANDES, W ;
SANTIAGO, T ;
LIMACHER, M .
CLINICAL CARDIOLOGY, 1990, 13 (10) :741-744
[7]   COMPARISON BETWEEN EFFECTS OF NITROPRUSSIDE AND NITROGLYCERIN ON ISCHEMIC-INJURY DURING ACUTE MYOCARDIAL-INFARCTION [J].
CHIARIELLO, M ;
GOLD, HK ;
LEINBACH, RC ;
DAVIS, MA ;
MAROKO, PR .
CIRCULATION, 1976, 54 (05) :766-773
[8]   L-GLUTAMATE EVOKES THE RELEASE OF AN ENDOTHELIUM-DERIVED RELAXING FACTOR-LIKE SUBSTANCE FROM THE RAT NUCLEUS-TRACTUS-SOLITARIUS [J].
DIPAOLA, ED ;
VIDAL, MJ ;
NISTICO, G .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 17 :S269-S272
[9]   INTRAVENOUS NITROGLYCERIN FOR THE TREATMENT OF CHRONIC CEREBRAL VASOCONSTRICTION IN THE PRIMATE [J].
FRAZEE, JG ;
GIANNOTTA, SL ;
STERN, WE .
JOURNAL OF NEUROSURGERY, 1981, 55 (06) :865-868
[10]   THE NITROVASODILATORS - NEW IDEAS ABOUT OLD DRUGS [J].
HARRISON, DG ;
BATES, JN .
CIRCULATION, 1993, 87 (05) :1461-1467